Skip to main content

Drug Interactions between cobimetinib and risdiplam

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

cobimetinib risdiplam

Applies to: cobimetinib and risdiplam

MONITOR: Theoretical concerns exist that oculotoxic effects of risdiplam, observed in monkeys, may be additive with those of other drugs that are associated with retinotoxicity. Chronic treatment of monkeys with risdiplam showed photoreceptor degeneration starting in the periphery of the retina. Upon cessation of treatment, the effects on the retinogram were partially reversible but the retinal degeneration, with peripheral photoreceptor loss, was irreversible. A no-effect dose for the retinal findings (1.5 mg/kg/day) in monkeys was associated with plasma exposures (AUC) like that in humans at the maximum recommended human dose (MRHD) of 5 mg. However, the potential for synergistic effects of concomitant administration of risdiplam with retinotoxic drugs has not been studied.

MANAGEMENT: Some authorities (AU) recommend caution when risdiplam is used concomitantly with known or suspected retinotoxic drugs. These drugs may include infigratinib, selumetinib, cobimetinib, vigabatrin, chloroquine, hydroxychloroquine, thioridazine and deferoxamine.

References

  1. (2002) "Product Information. Aralen (chloroquine)." Sanofi Winthrop Pharmaceuticals
  2. (2001) "Product Information. Desferal (deferoxamine)." Novartis Pharmaceuticals
  3. (2022) "Product Information. Plaquenil (hydroxychloroquine)." Apothecon Inc
  4. (2001) "Product Information. Mellaril (thioridazine)." Sandoz Pharmaceuticals Corporation
  5. (2005) "Product Information. Chloroquine Phosphate (chloroquine)." West Ward Pharmaceutical Corporation
  6. Cerner Multum, Inc. "UK Summary of Product Characteristics."
  7. Cerner Multum, Inc. "Australian Product Information."
  8. (2009) "Product Information. Sabril (vigabatrin)." Lundbeck Inc
  9. (2015) "Product Information. Deferoxamine Mesylate (deferoxamine)." Hospira Inc
  10. Cerner Multum, Inc (2015) "ANVISA Bulário Eletrônico."
  11. (2015) "Product Information. Cotellic (cobimetinib)." Genentech
  12. (2017) "Product Information. Hydroxychloroquine Sulfate (hydroxychloroquine)." Prasco Laboratories
  13. (2019) "Product Information. Thioridazine Hydrochloride (thioridazine)." Mylan Institutional (formerly UDL Laboratories)
  14. (2020) "Product Information. Koselugo (selumetinib)." Astra-Zeneca Pharmaceuticals
  15. (2021) "Product Information. Truseltiq (infigratinib)." QED Therapeutics Inc
View all 15 references

Switch to consumer interaction data

Drug and food interactions

Moderate

cobimetinib food

Applies to: cobimetinib

MONITOR: Grapefruit juice may increase the plasma concentrations of orally administered drugs that are substrates of the CYP450 3A4 isoenzyme, such as cobimetinib. However, the interaction seems to affect primarily those drugs that undergo significant presystemic metabolism by CYP450 3A4 (i.e., drugs with low oral bioavailability), presumably due to the fact that grapefruit juice inhibits primarily intestinal rather than hepatic CYP450 3A4. Because pharmacokinetic interactions involving grapefruit juice are often subject to a high degree of interpatient variability, the extent to which a given patient may be affected is difficult to predict.

MANAGEMENT: Patients who regularly consume grapefruit or grapefruit juice should be monitored for adverse effects and altered plasma concentrations of cobimetinib. Grapefruit and grapefruit juice should be avoided if an interaction is suspected. Orange juice is not expected to interact with these drugs.

References

  1. Cerner Multum, Inc. "UK Summary of Product Characteristics."
  2. (2015) "Product Information. Cotellic (cobimetinib)." Genentech

Switch to consumer interaction data

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer